GSK's Major Drug Acquisition
GSK acquires US-based Nuvalent for £8bn, bolstering its lung cancer drug pipeline and growth prospects
GSK has agreed to buy US lung cancer drug specialist Nuvalent for $10.6 billion (£8 billion) — its biggest deal in over a decade, according to GSK. The British pharmaceutical giant will pay $124 per share in cash, a 40% premium over Nuvalent's last closing price of $88.49, Reuters reported.
The deal gives GSK three new lung cancer drugs. Two are already under review by the US Food and Drug Administration, with decisions expected later in 2026. GSK CEO Luke Miels said the two lead products are "potential best-in-class assets that could launch this year if approved by the FDA."
GSK's Biggest Cancer Bet Since Selling Its Oncology Unit
The acquisition is GSK's largest since a 2014 asset swap with Novartis, in which GSK sold off its entire oncology portfolio in exchange for vaccines, according to Financial Times. The company has spent years trying to rebuild its cancer pipeline. Recent buys include Sierra Oncology, IDRx, RAPT Therapeutics ($2.2bn), and 35Pharma ($950m).
The Nuvalent deal is the crown jewel of that rebuilding effort. It targets two specific genetic mutations — ROS1-positive and ALK-positive — found in Non-Small Cell Lung Cancer (NSCLC). These mutations mainly affect non-smoking adults aged 40 to 50. Existing drugs often stop working as the cancer develops resistance. Nuvalent's drugs are designed to overcome that problem.
Two FDA Decisions Could Make or Break the Deal
Nuvalent's lead drug, neladalkib, targets ALK-positive lung cancer. The FDA has set a review deadline of November 27, 2026. A second drug, zidesamtinib, targets ROS1-positive cancer, with an FDA deadline of September 18, 2026, according to Morningstar. Both approvals are far from guaranteed. If the FDA rejects either drug, GSK could be sitting on billions of dollars of unapproved assets.
Analysts at Bernstein called Nuvalent their "best idea and top pick" before the deal, citing the strong clinical data behind both drugs, according to TipRanks. But others flagged the risk. The Global Banking & Finance Review noted the "hefty premium" paid for drugs that still need regulatory sign-off.
A Patent Cliff Forces GSK to Act Fast
GSK's urgency is not just about ambition. The company faces a looming "patent cliff" — when a drug's patent expires and cheap copies flood the market. Its blockbuster HIV drug dolutegravir loses patent protection between 2028 and 2030, according to City AM. GSK has set a revenue target of more than £40 billion by 2031. Without new growth drivers, that target looks hard to hit.
Nuvalent's lead drug, neladalkib, is projected to generate peak annual sales of $823 million, according to Intellectia.AI. GSK said the deal will be accretive — meaning it adds to earnings per share — by 2029. Sales contributions are expected to begin in 2027. The company confirmed it will hold its 70p dividend for 2026.
A Record Year for Pharma Dealmaking Backdrop
This deal does not stand alone. Biopharma M&A has hit $211 billion in the first half of 2026, according to data from Dealogic cited by Investing.com. Big drug companies are racing to fill pipelines before older blockbusters lose patent protection. GSK's new CEO Luke Miels, who took the top job in January 2026, has made acquisitions a central pillar of his strategy from day one.
The deal is expected to close in the third quarter of 2026, pending approval from regulators and Nuvalent shareholders. The net cost to GSK, after accounting for Nuvalent's existing cash, is $9.4 billion, according to Morningstar.
Sentiment
NeutralPublishers
12
Articles
11
Reach
12
